![In 2022, Dongfang Baitai Innovation and Transcendence, and Open a New Prospect In 2022, Dongfang Baitai Innovation and Transcendence, and Open a New Prospect](static/picture/b0b4e292-b9dd-4711-8708-37baac26f925.jpg_{i}xaf.jpg)
2022
東方百泰 Company profile
北京東方百泰生(shēng)物科(kē)技股份有限公司成立于2011年(nián),坐(zuò)落于亦莊經濟技術(shù)開發區,公司總占地面積6萬平方米,是國(guó)内的抗體(tǐ)藥物研發、生(shēng)産及銷售企業。公司産品類别主要以全人(rén)源單抗、人(rén)源化單抗、雙特異抗體(tǐ)、抗體(tǐ)融合蛋白(bái)、治療性疫苗等爲主,适應症涵蓋惡性腫瘤、糖尿病、自(zì)身(shēn)免疫性疾病(類風(fēng)濕性關節炎、銀屑病、強直性脊柱炎等)、高血脂症、哮喘等衆多高發性疾病。
公司擁有上百人(rén)專業抗體(tǐ)研發團隊,布局了20多餘項研發管線,先後承擔了多項國(guó)家“重大(dà)新藥創制”、部委專項課題和“863”計(jì)劃等十一五、十二五重點項目。東方百泰始終将"品質與創新"作(zuò)爲企業的永恒追求。公司始終堅持以創新爲企業發展的源動力,注重産業轉化,其位于北京亦莊新的大(dà)規模産業基地正在建設中,總投資将達15億,其中一期占地30畝,屆時将建成一條3*3000L,符合中國(guó)、美國(guó)GMP要求的先進水平的抗體(tǐ)生(shēng)産線。預計(jì)2022年(nián)投入使用。
DONGFANG BAITAI Company profile
Located in Yizhuang’s Economic and Technological Development Area with a total area of about 60000 square meters, Eastern Biotech was founded in 2011 and became a leading biomedical R&D, production and sales company in China. The company's product categories include full human monoclonal antibody, humanized monoclonal antibody, bispecific antibody, antibody fusion protein, therapeutic vaccine, to name a few that target prevalent diseases such as malignant tumors, diabetes, autoimmune diseases (rheumatoid arthritis, psoriasis, ankylosing spondylitis, etc.), ophthalmic diseases, respiratory diseases, etc.
Here at Beijing Eastern Biotech, we have a biological drug research and development team with more than 100 people who laid out more than 20 research and development pipelines, obtained 7 approval documents for clinical trials of new drugs, and are conducting clinical trial research. We have undertaken a number of national "major new drug development", special projects of various ministries and commissions, the "863" plan and other key projects such as the 11th and 12th Five Year Plan. We always hold "quality and innovation" as the eternal pursuit and source of power for the company and remain attentive towards changes in the industry.
Our new large-scale industrial base in Yizhuang, Beijing, is under construction with a total investment of 1.5 billion yuan. The first phase covers an area of 30 mu (about 4.9 acres) where a 3 * 2000L mammal batch cultivation production line will be built. It will meet the advanced requirements of China and the United States GMP, and it is expected to be officially put into use in 2023.
Dongfang Baitai Biopharmaceutical Co., Ltd. (or Eastern Pharmaceutical), a subsidiary of Eastern Biotech, is one of the earliest companies to be engaged in antibody drug development in China. Its core product Tai Xin Sheng® (nimotuzumab) is the first humanized monoclonal antibody drug targeting nasopharyngeal cancer China, and it has a therapeutic effect on many other cancers such as: head and neck, pancreatic, breast, glioma, non-small cell lung, etc. It was added to the Chinese Pharmacopoeia in 2015 and the national medical insurance in 2017, significantly contributing to the field of biomedical antibodies in China!
Eastern Biotech has been successively awarded the titles of "Beijing Engineering Laboratory of Antibody Project" and "Beijing Engineering Research Center of Antibody Drugs". It is not only the "Beijing International Science and Technology Cooperation Base for New Antibody and Therapeutic Protein Drugs", but also the "National International Science and Technology Cooperation Base for Advanced Technologies of New Antibody and Therapeutic Protein Drugs". We have successively established a "Postdoctoral Scientific Research Workstation" a "Academician Expert Workstation", and we are certified by the national intellectual property management system and the International Organization for Standardization (ISO 9000).
2011year
Date of establishment
20+
R&D pipeline layout
50%+
Percentage of doctors and masters
100+
Invention patent
3*2000L
Large scale production line
The enterprise culture
Corporate mission
Gather the power of biomedicine
Create a healthy life for human beings
Corporate philosophy
The Doctors
The conscience of the druggist
Corporate Vision
Protect life and health
Become an international first-class pharmaceutical group with leading technology
Core values
Responsibility: responsibility, integrity and perseverance
Quality: profession, reputation and pursuit
Innovation: exploration, attitude, change
Health: spirit, life, care
The development course
2022 |
● Dongfang Baitai has been certified by ISO9000(Quality Management system certification, environmental management system certification and Occupational health and safety management system certification).
2021 |
● Top 100 Private Enterprises in Beijing 2020
● Dongfang Baitai has been recognized as "Beijing specialized in special and new small giant Enterprise".
● Dongfang Baitai won the title of "China's New Pharmaceutical Innovation Force in 2021".
● JY025 won the "China Patent Excellence Award".
● Dongfang Baitai won the "First Prize of Independent Innovation Achievements of Capital Employees in 2020".
2020 |
● Dongfang Baitai was recognized as "Beijing Enterprise Technology Center"
● Dongfang Baitai was recognized as "Municipal Employee Innovation Studio for bio-drug Development of Major Diseases".
● Dongfang Baitai was recognized as "Municipal Employee Innovation Studio for bio-drug Development of Major Diseases".
● JY016 won the "14th Beijing Innovation Competition Public Innovation Award"
● JY09 won the 21st China Patent Silver Award
● Dongfang Baitai was recognized as "Beijing Intellectual Property Demonstration Unit"
●"Beijing Dongfang Baitai Biotechnology Co., LTD." completed the share reform and changed its name to "Beijing Dongfang Baitai Biotechnology Co., LTD."
2019 |
●Dongfang Baitai is recognized as the "Home of Science and Technology Workers"
● Dongfang Baitai won the Second Prize of "2018 Capital Employees' Independent Innovation Achievements"
● Dongfang Baitai won the second Prize of "2019 Maker China Beijing smes Innovation and Entrepreneurship Competition" (Enterprise Group)
● Dongfang Baitai was identified as "Industrial Enterprise Intellectual Property Application Pilot Enterprise"
2018 |
● Dongfang Baitai won the "National Intellectual Property Management System Certification"
● JY025 has been approved for clinical trials
● Antibody drug research and development and industrialization base engineering capping
2017 |
● Academician expert Research station was officially established
● The post-doctoral research station was officially established
● JY09 won the first prize of "2016 Capital Employees Independent Innovation Achievement"
● JY028(AMD) has been approved for clinical trials
● Antibody drug research and development and industrialization base project is under construction
● JY026 has been approved for clinical trials
● JY028 has been approved for clinical trials
2016 |
● Dongfang Baitai has been recognized as the "International scientific and Technological Cooperation Base for New Antibody and therapeutic protein Drug Frontier Technology".
● "JY09" won "T100 New Products and New Technology"
● "JY09" won "T100 New Products and New Technology"
● "JY09" has been approved for clinical trials
2015 |
● The holding subsidiary "Baitai Biological Pharmaceutical Co., LTD." marks the 15th anniversary of its establishment
● Dongfang Baitai was recognized as the "Innovation Studio for Biological drug Development Staff".
2014 |
● Dongfang Baitai was recognized as "Zhongguancun High-tech Enterprise"
● Dongfang Baitai was recognized as "Beijing International Science and Technology Cooperation Base for New Antibody and Therapeutic Protein Drug Frontier Technology".
● Dongfang Baitai won the "Patent Pilot Certificate"
2013 |
● Dongfang Baitai was recognized as "Beijing Engineering Research Center for Antibody Drugs".
2011 |
● Dongfang Baitai was identified as "Beijing Engineering Laboratory of Antibody Engineering"
● Dongfang Baitai was recognized as "Beijing Genetic Engineering Antibody Drug Engineering Technology Research Center"
● Beijing Dongfang Baitai Biotechnology Co., LTD was established
2008 |
● "Beijing Jingyi Taixiang Technology Development Co., LTD." was restructured to prepare for the establishment of "Beijing Dongfang Baitai Biotechnology Co., LTD."
企業文化 The enterprise culture
使命:凝聚生(shēng)物醫藥力量,創享人(rén)類生(shēng)活健康
理(lǐ)念:醫者仁心,藥者良心
願景:守護生(shēng)命健康,成爲技術(shù)的制藥集團
核心價值觀
責任: 擔當、誠信、堅守,乃企業立足之根本。
品質: 專業、信譽、追求,乃企業永恒之基石。
創新: 探索,态度,變革,乃企業長青之保障。
健康: 精神,生(shēng)命,關愛,乃企業奮鬥之目标。
發展曆程 The development course
Follow us
Follow the official WeChat official account
Or search "Oriental Baitai"
More exciting waiting for you!
Address: No. 2, Rongjing East Street, Beijing Economic and Technological Development Zone
Tel.: 010-51571019
Email: ebt@east-bt.com
Copyright 2021 Beijing Dongfang Baitai Biotechnology Co., Ltd SEO